Zimmer BioTech Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $8.16M
Latest Deal Amount
  • Investors
  • 2

Zimmer BioTech General Information

Description

Provider of drug research and development services intended to be used for the treatment of actinic keratoses in combination with photodynamic therapy. The company's platform offers a drug based on the compound 5-Aminolevulinic acid that is used to treat skin cancer, enabling doctors to treat patients effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • Neu-Ulm
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zimmer BioTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 09-Aug-2017 $8.16M 00.000 000.00 Completed Startup
To view Zimmer BioTech’s complete valuation and funding history, request access »

Zimmer BioTech Executive Team (1)

Name Title Board Seat Contact Info
Armin Zimmer Chief Executive Officer
To view Zimmer BioTech’s complete executive team members history, request access »

Zimmer BioTech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Zimmer MedizinSysteme Other Minority 000 0000 000000 0
To view Zimmer BioTech’s complete investors history, request access »